Back to results
US 2020/0348307 A1Published application
Methods and compositions for polypeptide analysis
AssigneeEncodia, Inc.
InventorsJohn M. BEIERLE, Robert C. JAMES, Luca MONFREGOLA, Kevin GUNDERSON, Michael LEBL, Lei SHI
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods and kits for analysis of polypeptides. In some embodiments, the present methods and kits employ barcoding and nucleic acid encoding of molecular recognition events, and/or detectable labels.
Claims30
A method for analyzing a polypeptide, comprising the steps of:
- (a) providing the polypeptide optionally associated directly or indirectly with a recording tag;
- and optionally contacting the polypeptide with a proline aminopeptidase under conditions suitable to cleave an N-terminal proline;
- (b) functionalizing the N-terminal amino acid (NTAA) of the polypeptide with a chemical reagent, wherein the chemical reagent comprises a compound selected from the group consisting of
- (i) a compound of Formula (I):
- or a salt or conjugate thereof,
- wherein
- R1 and R2 are each independently H, C1-6alkyl, cycloalkyl, —C(O)Ra, —C(O)ORb, or —S(O)2Rc;
- Ra, Rb, and Rc are each independently H, C1-6alkyl, C1-6haloalkyl, arylalkyl, aryl, or heteroaryl, wherein the C1-6alkyl, C1-6haloalkyl, arylalkyl, aryl, and heteroaryl are each unsubstituted or substituted;
- R3 is heteroaryl, —NRdC(O)ORe, or —SRf, wherein the heteroaryl is unsubstituted or substituted;
- Rd, Re, and Rf are each independently H or C1-6alkyl;
- and
- optionally wherein when R3 is
- R1 and R2 are not both H;
- (ii) a compound of Formula (II):
- or a salt or conjugate thereof,
- wherein
- R4 is H, C1-6alkyl, cycloalkyl, —C(O)Rg, or —C(O)ORg;
- and
- Rg is H, C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, or arylalkyl, wherein the C1-6alkyl, C2-6alkenyl, C1-6 haloalkyl, and arylalkyl are each unsubstituted or substituted;
- (iii) a compound of Formula (III):
- R5—N═C═S (III)
- or a salt or conjugate thereof,
- wherein
- R5 is C1-6alkyl, C2-6 alkenyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;
- wherein the C1-6alkyl, C2-6 alkenyl, cycloalkyl, heterocyclyl, aryl or heteroaryl are each unsubstituted or substituted with one or more groups selected from the group consisting of halo, —NRhRi, —S(O)2Rj, or heterocyclyl;
- Rh, Ri, and Rare each independently H, C1-6alkyl, C1-6haloalkyl, arylalkyl, aryl, or heteroaryl, wherein the C1-6alkyl, C1-6haloalkyl, arylalkyl, aryl, and heteroaryl are each unsubstituted or substituted;
- (iv) a compound of Formula (IV):
- or a salt or conjugate thereof,
- wherein
- R6 and R7 are each independently H, C1-6alkyl, —CO2C1-4 alkyl, —ORk, aryl, or cycloalkyl, wherein the C1-6alkyl, —CO2C1-4 alkyl, —ORk, aryl, and cycloalkyl are each unsubstituted or substituted;
- and
- Rk is H, C1-6alkyl, or heterocyclyl, wherein the C1-6alkyl and heterocyclyl are each unsubstituted or substituted;
- (v) a compound of Formula (V):
- or a salt or conjugate thereof,
- wherein
- R8 is halo or —ORm;
- Rm is H, C1-6alkyl, or heterocyclyl;
- and
- R9 is hydrogen, halo, or C1-6haloalkyl;
- (vi) a metal complex of Formula (VI):
- MLm (VI)
- or a salt or conjugate thereof,
- wherein
- M is a metal selected from the group consisting of Co, Cu, Pd, Pt, Zn, and Ni;
- L is a ligand selected from the group consisting of —OH, —OH2, 2,2′-bipyridine (bpy), 1,5 dithiacyclooctane (dtco), 1,2-bis(diphenylphosphino)ethane (dppe), ethylenediamine (en), and triethylenetetramine (trien);
- and
- n is an integer from 1-8, inclusive;
- wherein each L can be the same or different;
- and
- (vii) a compound of Formula (VII):
- or a salt or conjugate thereof,
- wherein
- G1 is N, NR13, or CR13R14;
- G2 is N or CH;
- p is 0 or 1;
- R10, R11, R12, R13, and R14 are each independently selected from the group consisting of H, C1-6alkyl, C1-6haloalkyl, C1-6alkylamine, and C1-6 alkylhydroxylamine, wherein the C1-6alkyl, C1-6haloalkyl, C1-6alkylamine, and C1-6alkylhydroxylamine are each unsubstituted or substituted, and R10 and R11 can optionally come together to form a ring;
- and
- R15 is H or OH;
- (c) contacting the polypeptide with a first binding agent comprising a first binding portion capable of binding to the functionalized NTAA and
- (c1) a first coding tag with identifying information regarding the first binding agent, or
- (c2) a first detectable label;
- (d) (d1) transferring the information of the first coding tag to the recording tag to generate an extended recording tag and analyzing the extended recording tag, or
- (d2) detecting the first detectable label;
- wherein step (b) is conducted before step (c), after step (c) and before step (d), or after step (d).
61 more elements
3-5. (canceled)
7-8. (canceled)
10-12. (canceled)
15-16. (canceled)
18-20. (canceled)
(canceled)
26-27. (canceled)
29-30. (canceled)
33-281. (canceled)
A kit for sequencing a polypeptide comprising:
- (a) a reagent for affixing the polypeptide to a support or substrate, or a reagent for providing the polypeptide in a solution;
- (b) a reagent for functionalizing the N-terminal amino acid (NTAA) of the polypeptide, wherein the reagent comprises a compound selected from the group consisting of
- (i) a compound of Formula (I):
- or a salt or conjugate thereof,
- wherein
- R1 and R2 are each independently H, C1-6alkyl, cycloalkyl, —C(O)Ra, —C(O)ORb, or —S(O)2Rc;
- Ra, Rb, and Rc are each independently H, C1-6alkyl, C1-6haloalkyl, arylalkyl, aryl, or heteroaryl, wherein the C1-6alkyl, C1-6haloalkyl, arylalkyl, aryl, and heteroaryl are each unsubstituted or substituted;
- R3 is heteroaryl, —NRdC(O)ORe, or —SRf, wherein the heteroaryl is unsubstituted or substituted;
- Rd, Re, and Rf are each independently H or C1-6alkyl;
- and
- optionally wherein when R3 is
- R1 and R2 are not both H;
- (ii) a compound of Formula (II):
- or a salt or conjugate thereof,
- wherein
- R4 is H, C1-6alkyl, cycloalkyl, —C(O)Rg, or —C(O)ORg;
- and
- Rg is H, C1-6alkyl, C2-6alkenyl, C1-6haloalkyl, or arylalkyl, wherein the C1-6alkyl, C2-6alkenyl, C1-6 haloalkyl, and arylalkyl are each unsubstituted or substituted;
- (iii) a compound of Formula (III):
- R5—N═C═S (III)
- or a salt or conjugate thereof,
- wherein
- R5 is C1-6alkyl, C2-6 alkenyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;
- wherein the C1-6alkyl, C2-6 alkenyl, cycloalkyl, heterocyclyl, aryl or heteroaryl are each unsubstituted or substituted with one or more groups selected from the group consisting of halo, —NRhRi, —S(O)2Rj, or heterocyclyl;
- Rh, Ri, and Rj are each independently H, C1-6alkyl, C1-6haloalkyl, arylalkyl, aryl, or heteroaryl, wherein the C1-6alkyl, C1-6haloalkyl, arylalkyl, aryl, and heteroaryl are each unsubstituted or substituted;
- (iv) a compound of Formula (IV):
- or a salt or conjugate thereof,
- wherein
- R6 and R7 are each independently H, C1-6alkyl, —CO2C1-4 alkyl, —ORk, aryl, or cycloalkyl, wherein the C1-6alkyl, —CO2C1-4 alkyl, —ORk, aryl, and cycloalkyl are each unsubstituted or substituted;
- and
- Rk is H, C1-6alkyl, or heterocyclyl, wherein the C1-6alkyl and heterocyclyl are each unsubstituted or substituted;
- (v) a compound of Formula (V):
- or a salt or conjugate thereof,
- wherein
- R8 is halo or —ORm;
- Rm is H, C1-6alkyl, or heterocyclyl;
- and
- R9 is hydrogen, halo, or C1-6haloalkyl;
- (vi) a metal complex of Formula (VI):
- MLn (VI)
- or a salt or conjugate thereof,
- wherein
- M is a metal selected from the group consisting of Co, Cu, Pd, Pt, Zn, and Ni;
- L is a ligand selected from the group consisting of —OH, —OH2, 2,2′-bipyridine (bpy), 1,5 dithiacyclooctane (dtco), 1,2-bis(diphenylphosphino)ethane (dppe), ethylenediamine (en), and triethylenetetramine (trien);
- and
- n is an integer from 1-8, inclusive;
- wherein each L can be the same or different;
- and
- (vii) a compound of Formula (VII):
- or a salt or conjugate thereof,
- wherein
- G1 is N, NR13, or CR13R14;
- G2 is N or CH;
- p is 0 or 1;
- R10, R11, R12, R13, and R14 are each independently selected from the group consisting of H, C1-6alkyl, C1-6haloalkyl, C1-6alkylamine, and C1-6alkylhydroxylamine, wherein the C1-6alkyl, C1-6haloalkyl, C1-6alkylamine, and C1-6alkylhydroxylamine are each unsubstituted or substituted, and R10 and R11 can optionally come together to form a ring;
- and
- R15 is H or OH;
- and
- (c) a binding agent comprising a binding portion capable of binding to the functionalized NTAA and a detectable label;
- and optionally further comprising a proline aminopeptidase.
57 more elements
287-298. (canceled)
Dependencies are inferred from the claim text.